This review highlights the impact of the PI3K/AKT/mTOR pathway on cancer stem cells, suggesting potential therapeutic targeting to control proliferation and migration.
Cancer stem cells (CSCs) are a small subpopulation bearing self-renewal ability, mediating tumor initiation and propagation. Several molecular pathways, including the PI3K/AKT/mTOR pathway, are known to be aberrantly activated in cancers. In CSCs, PI3K/AKT/mTOR pathway has been associated with attribution of various properties to cancer cells including stemness characteristics, proliferation, migration, epithelial to mesenchymal transition, and autophagy. Thus, targeting PI3K/AKT/mTOR pathway with novel inhibitors might help to control the growth and proliferation of the breast CSC population. Though many studies have focused on PI3K/AKT/mTOR pathway in breast cancer, limited literature is available on the role of PI3K/AKT/mTOR pathway in breast CSCs. Here, in our present review, we have highlighted the role of the PI3K/AKT/mTOR signaling pathway in breast CSCs and its applications in therapeutic targeting.
No takes yet. Share an insight, caveat, or question.
Prabhu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: